EDITHIGH SIGNALFINANCIAL10-K

EDIT experienced severe financial deterioration with stockholders' equity collapsing 79.7% to just $27.3M while dramatically cutting R&D spending by 54.9%, signaling potential liquidity concerns and strategic pivot away from broad development programs.

The massive decline in stockholders' equity to $27.3M combined with continued operating losses of $160M annually suggests EDIT is approaching a critical financial juncture that may require immediate capital raising or strategic alternatives. The company's shift to focusing exclusively on lead candidate EDIT-401 and the 55% reduction in R&D spending indicates a forced narrowing of its pipeline to preserve cash, which reduces diversification and increases concentration risk.

Comparing 2026-03-09 vs 2025-03-05View on EDGAR →
FINANCIAL ANALYSIS

EDIT's financials show a company in severe distress, with stockholders' equity plummeting 79.7% to just $27.3M while total assets declined 45.4% to $186.5M, indicating significant cash burn and potential dilutive financing. Although operating cash flow improved 21.4% and R&D expenses were slashed 54.9%, the company continues burning substantial cash with $160M in operating losses, creating an urgent need for capital. The dramatic reduction in capital expenditures from $8.8M to $607K further signals cost-cutting measures as the company likely approaches a financial inflection point.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-93.1%
$8.8M→$607K

Capex reduced 93.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-79.7%
$134.3M→$27.3M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
-54.9%
$199.2M→$90.0M

R&D spending cut 54.9% — could signal cost discipline or concerning reduction in innovation investment.

Total Assets
Balance Sheet
-45.4%
$341.6M→$186.5M

Total assets contracted 45.4% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-43.4%
$289.3M→$163.9M

Current assets declined 43.4% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
-40.1%
$77.2M→$46.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Operating Income
P&L
+36.3%
-$251.2M→-$160.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+32.5%
-$237.1M→-$160.1M

Net income grew 32.5% — bottom-line growth signals improving overall business health.

Total Liabilities
Balance Sheet
-23.2%
$207.3M→$159.2M

Liabilities reduced 23.2% — deleveraging improves balance sheet strength and financial flexibility.

Operating Cash Flow
Cash Flow
+21.4%
-$210.3M→-$165.2M

Operating cash flow grew 21.4% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-05
ADDED
Form 10-K Summary 161 SIGNATURES 162 2 Table of Co ntents References to Editas Throughout this Annual Report on Form 10-K, the Company, Editas, Editas Medicine, we, us, and our, except where the context requires otherwise, refer to Editas Medicine, Inc.
3 Table of Co ntents Risk Factor Summary We are dependent on the success of our lead product candidate, EDIT-401, which is in preclinical development.
If we are unable to commence and complete the clinical development of, obtain marketing approval for, or successfully commercialize EDIT-401, either alone or with a collaborator, or if we experience significant delays in doing so, our business would be substantially harmed.
The gene editing field is relatively new and is evolving rapidly.
We are focusing our research and development efforts on CRISPR gene editing technology using Cas9 and Cas12a enzymes, but other gene editing technologies may be discovered that provide significant advantages over CRISPR/Cas9 or CRISPR/Cas12a, which could materially harm our business.
Preclinical testing and clinical trials of product candidates, including EDIT-401, may not be successful.
If we are unable to commercialize any product candidates we develop or experience significant delays in doing so, our business will be materially harmed.
We have not tested any of our proposed delivery modes, combined with our product candidates, in clinical trials and have not begun clinical trials in any of our current development programs.
Our rights to develop and commercialize our technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.
Our Strategy We seek to be a leader in in vivo gene editing, leveraging cutting edge gene editing technology to deliver transformative therapies that simplify the usability for patients, minimize the burdens to patients and healthcare systems, and are meaningfully differentiated from the current standards of care, while also allowing a simple, scalable manufacturing process to reduce costs to manufacture and administer the therapies.
REMOVED
We intend to identify and develop product candidates based on a relatively novel genome editing technology, which makes it difficult to predict the time and cost of product candidate development.
The genome editing field is relatively new and is evolving rapidly.
We are focusing our research and development efforts on CRISPR gene editing technology using Cas9 and Cas12a enzymes, but other genome editing technologies may be discovered that provide significant advantages over CRISPR/Cas9 or CRISPR/Cas12a.
Preclinical testing and clinical trials of product candidates may not be successful.
We have not extensively tested any of our proposed delivery modes in clinical trials and have not begun clinical trials in any of our current development programs.
Our Strategy We seek to be a leader in in vivo programmable gene editing, leveraging cutting edge gene editing technology to deliver therapies that simplify the usability for patients, minimize the burdens to patients and healthcare systems, and are meaningfully differentiated from the current standards of care, while also allowing a simpler, more scalable manufacturing process that can reduce costs to manufacture and administer the therapies relative to ex vivo treatments.
We are able to upregulate by editing regulatory sequences upstream and downstream of a gene, which allows us to address those diseases where the gene knockdown approach, which aims to reduce the expression of one or more targeted genes, will not be effective.
Further, upregulation enables us to create treatments designed for most or all patients with the same disease, regardless of the specific genetic mutation causing the disease.
We previously demonstrated proof of concept of our functional upregulation strategy in our clinical trials of renizgamglogene autogedtemcel ( reni-cel ), an experimental ex vivo gene-edited medicine to treat sickle cell disease ( SCD ), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia ( TDT ), the most severe form of beta-thalassemia, an inherited blood disorder characterized by severe anemia.
In our former reni-cel program, we used our indel CRISPR technology to upregulate the expression of the gamma globin gene, a functional homolog of the beta globin gene, through direct editing of the HBG1/2 promotor site using our highly specific and efficient proprietary engineered AsCas12a enzyme.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →